Nattachai Srisawat
Chulalongkorn University · Excellence Center of Critical Care Nephrology, Chulalongkorn University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nattachai Srisawat as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:54 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06034990 · ICU Fluid Utilization Survey in Southeast AsiaChulalongkorn University · completed · Critical Illness · principal investigator
- Ph2/Ph3NCT06030843 · The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1Chulalongkorn University · recruiting · Empagliflozin in Cardiorenal Syndrome Type 1 · principal investigator
- Ph1NCT05360615 · The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury SurvivorsChulalongkorn University · active not recruiting · Empagliflozin in Post AKI Stage 2-3 · principal investigator
- N/ANCT02730117 · Furosemide Stress Test Guiding Initiation of Renal Replacement TherapyChulalongkorn University · completed · Acute Kidney Injury · principal investigator
- N/ANCT01819038 · Early Renal Replacement Therapy and the Outcome of Acute Kidney InjuryChulalongkorn University · completed · Acute Renal Failure · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Identification of predictive biomarkers for severe acute leptospirosis and its long-term sequelaeR01AI183353 · NIAID · CHULALONGKORN UNIVERSITY · fiscal years 2024 to 2026 · $136,828 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:54 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Urinary biomarkers and renal recovery in critically ill patients with renal support.Clin J Am Soc Nephrol · 2011129 citationsRCR 4.4
- 120 citationsRCR 6.0
- The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients.Crit Care · 201860 citationsRCR 2.5
- Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration.Ther Apher Dial · 201153 citationsRCR 2.0
- Comprehensive versus standard care in post-severe acute kidney injury survivors, a randomized controlled trial.Crit Care · 202147 citationsRCR 3.4
- Plasma syndecan-1 is associated with fluid requirements and clinical outcomes in emergency department patients with sepsis.Am J Emerg Med · 202138 citationsRCR 2.7
- Enhanced vascular endothelial growth factor and inflammatory cytokine removal with online hemodiafiltration over high-flux hemodialysis in sepsis-related acute kidney injury patients.Ther Apher Dial · 201317 citationsRCR 0.7
- Lower-Dosage Acute Peritoneal Dialysis versus Acute Intermittent Hemodialysis in Acute Kidney Injury: A Randomized Controlled Trial.Clin J Am Soc Nephrol · 202413 citationsRCR 2.9
- 12 citationsRCR 0.6
- The role of neutrophil chemotaxis activity as an immunologic biomarker to predict mortality in critically-ill patients with severe sepsis.J Crit Care · 202012 citationsRCR 0.7